PETRI DISH PERSPECTIVES
PETRI DISH PERSPECTIVES
Manead Khin
December 2025: Biotech & Pharma NEWS Roundup
10 minutes Posted Jan 1, 2026 at 11:00 am.
Novartis has entered a significant $1.7 billion strategic partnership with London-based TechBio firm Relation Therapeutics
GSK has officially offloaded its bioelectronic-focused venture unit
340B Drug Pricing Program reached a record $81 billion in sales in 2024, representing a massive 23% year-over-year increase
Regeneron and Tessera Therapeutics have entered a global collaboration to develop TSRA-196
Pfizer has secured an exclusive license for YP05002 from YaoPharma
US FDA has approved Exdensur (depemokimab), making it the first ultra-long-acting biologic for the treatment of severe eosinophilic asthma
Bristol Myers Squibb has inked a $1.1 billion collaboration with Harbour BioMed to discover and develop next-generation multi-specific antibodies
BioMarin has reached a definitive agreement to acquire Amicus Therapeutics for $4.8 billion
Shionogi has finalized a $2.5 billion agreement to acquire the global rights to the ALS medication Radicava (edaravone) from Tanabe Pharma
Sanofi has agreed to acquire Dynavax Technologies for approximately $2.2 billion
2025 Top 5 Pharma Valuations
0:00
10:32
Download MP3
Show notes
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for December 2025! This month was dominated by a surge in M&A activity and licensing deals. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.